The core therapeutic purpose of Artefan (Artemether/Lumefantrine) is used as an Artemisinin-Based Combination Therapy (ACT) for managing acute malarial infections.

This combination medicine is used to treat certain kinds of malaria infections. It is generally applied in settings where other antimalarial agents may not be effective due to drug resistance.

Addressing Acute, Uncomplicated Malaria

Artefan is commonly used as a primary therapeutic option for acute, uncomplicated infection due to the Plasmodium falciparum parasite. It is applied in addressing the parasite load in the bloodstream, supporting the process of parasite elimination, and may help manage the risk of the infection worsening. This medication is relevant for managing conditions characterized by periods of heightened symptoms, including fever, shaking chills, and systemic weakness.

Supporting Relief from Symptoms and Parasite Clearance

The medication is relevant for managing symptoms that create noticeable physiological strain, which often accompany an acute malaria attack. It generally helps ease the frequency and severity of symptoms related to heightened physiological activity, such as fever, shaking chills, severe headache, and widespread muscle aches. This provides supportive relief when symptoms interfere with routine activities, contributing to a more manageable experience. Furthermore, Artefan plays a role in supporting both parasite clearance and sustained elimination of residual parasites, which is a strategy aligned with managing infections in drug-resistant areas.

---

Quick Facts:

• Used in areas where drug resistance is a clinical concern.
• Supports relief from symptoms related to systemic imbalance (fever, chills, aches).

• Contributes to managing the risk of the infection returning (recrudescence).

Regulatory References

1. NIH MedlinePlus Drug Information

Who can and cannot use Artefan?

Artefan (Artemether/Lumefantrine) is officially indicated for the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum in patients who meet specific eligibility criteria, as detailed in regulatory documents.

---

Eligible Populations

• Adults and Children: The medicine is approved for use in patients who weigh 5 kg or more.
• Uncomplicated Malaria: Use is restricted to patients with non-severe malaria infections.

Contraindications (Who Must Not Use Artefan)

The medicine is formally contraindicated in several populations due to potential cardiac risk or hypersensitivity:

• Patients with known hypersensitivity to artemether, lumefantrine, or any components.
• Patients with a history of QTc interval prolongation (including congenital) or sudden death.
• Patients with clinically relevant bradycardia, symptomatic cardiac arrhythmias, or severe cardiac disease.
• Patients with known severe electrolyte disturbances, such as uncorrected hypokalemia or hypomagnesemia.

Restricted and Not Recommended Use

Population	Regulatory Status
Pregnancy (First Trimester)	Not recommended unless no other suitable, effective antimalarial is available.
Lactation/Breastfeeding	Not recommended.
Severe Organ Impairment	Caution is advised in severe hepatic or renal impairment due to limited safety data.
Infants < 5 kg	Safety and efficacy have not been established.

Use is also contraindicated with other medications known to prolong the QTc interval or strong CYP3A4 inducers, as stated in prescribing information.

Artefan (artemether and lumefantrine) can interact with several medicinal products, primarily by affecting the metabolism of one or both components or by having additive effects on heart rhythm. Artefan's components are mainly broken down by the CYP3A4 liver enzyme.

Interaction Type	Examples of Interacting Medicines or Products
Do Not Combine (Contraindicated)	Strong CYP3A4 Inducers: Rifampin, Carbamazepine, Phenytoin, St. John's wort. Use is contraindicated because they significantly reduce Artefan concentrations, potentially leading to treatment failure.
Use With Caution	QT-Prolonging Medicines: Including certain antiarrhythmics (e.g., Amiodarone, Quinidine) and other antimalarials (e.g., Quinine, Halofantrine). Co-administration may increase the risk of serious heart rhythm abnormalities. ECG monitoring may be required.
Use With Caution	Strong CYP3A4 Inhibitors: Including some HIV protease inhibitors and antifungals like Ketoconazole. These can increase the concentration of Artefan's components, raising the risk of QT prolongation.
Hormonal Contraceptives	Artefan may decrease the effectiveness of hormonal birth control (pills, patches, etc.). An alternative barrier method of contraception is recommended during and after treatment.

Co-administration with other antimalarial agents is generally discouraged unless no other options exist. Use is also cautioned in individuals with pre-existing conditions that affect the heart's electrical activity or who have electrolyte imbalances.

How Artefan Works: Dual-Action Mechanism

Artefan’s activity is governed by a dual-mechanism approach executed by its two active ingredients, ensuring both rapid parasiticidal action and sustained parasiticidal pressure against the asexual stage of the parasite.

Rapid Molecular Destruction via Endoperoxide Cleavage

The fast-acting component, Artemether, exploits the ferrous iron (Fe^2+) released from host hemoglobin inside the parasite. This iron triggers the cleavage of Artemether’s endoperoxide bridge, generating a burst of highly cytotoxic free radicals. This action causes massive, non-specific damage to essential parasite macromolecules and directly inhibits the PfATP6 enzyme, disrupting the parasite's calcium homeostasis. This cascade leads to a swift, substantial reduction in the circulating asexual parasite biomass.

Sustained Blockade of Heme Detoxification

The long-acting component, Lumefantrine, operates by interfering with the parasite’s heme detoxification pathway. By chemically complexing with the highly toxic heme released during hemoglobin digestion, Lumefantrine effectively blocks the parasite’s attempt to convert it into inert beta-hematin (malaria pigment). The resulting buildup of toxic heme within the parasite causes severe oxidative stress, maintaining a sustained parasiticidal effect against the asexual stage of the parasite.

How to Use Artefan (Artemether/Lumefantrine)

Artefan is an oral medicine prescribed as a fixed-dose combination tablet containing 20 mg of Artemether and 120 mg of Lumefantrine. Its administration is governed by a precise, standardized protocol to ensure adequate drug absorption.

---

Official Administration Protocol

The total treatment course is a fixed regimen of six doses administered over a 60-hour period (3 days). The standard dosing for patients weighing 35 kg or more is four tablets per dose. This medication is approved for use in patients who weigh at least 5 kg or are at least 2 months of age. Dosing for all patients is strictly determined by body weight, with the number of tablets per dose scaling accordingly.

Dosing Timing	Dose Interval	Tablets per Dose (35 kg or more)
Day 1 (Doses 1 & 2)	8 hours between the two doses	4 tablets per dose
Day 2 & 3 (Doses 3–6)	12 hours between doses (twice daily)	4 tablets per dose

---

Contextual Usage Principles

Every dose of Artefan must be taken with food or a milky drink to significantly enhance the medicine’s systemic absorption, which is a foundational requirement for proper use. If a dose is administered and the patient vomits within 1 to 2 hours, the full dose must be repeated immediately to maintain the treatment course. For patients who cannot swallow the tablets whole, they may be crushed and mixed with a small amount of water for immediate consumption, followed by food.

Research evidence / Overview of Studies for Artefan

---

Evidence for Use in Acute, Uncomplicated Malaria Infection

The Artemether/Lumefantrine combination was studied for acute, uncomplicated infections caused by the Plasmodium falciparum parasite, especially in research exploring areas where drug resistance is a concern. The evidence base is primarily built upon Randomized Controlled Trials (RCTs), which are foundational in evaluating research, and comprehensive Systematic Reviews that combine data from many different trials.

These studies focused on research exploring short-term symptom changes and examined outcomes related to systemic or functional imbalance. Researchers examined how quickly the parasite was cleared from the blood (Parasite Clearance Time) and how fast the patient's fever resolved (Fever Clearance Time). Findings from these large-scale trials and pooled analyses describe patterns observed where measurements of parasite and fever clearance were monitored over short time intervals in the observed populations. Furthermore, research monitored the rate of Adequate Clinical and Parasitological Response (ACPR), a key measure used in studies evaluating outcomes at follow-up points of 28 days and 42 days.

Study Outcomes and Measures of Response

Research efforts primarily focused on outcomes related to systemic or functional imbalance caused by the malaria infection. The main goal in the studies was to explore outcomes related to parasite burden and recurrent parasitemia (recrudescence). This was done by continuously monitoring the number of parasites present in the blood, often using sensitive laboratory techniques, to determine the time to parasite clearance.

Additionally, trials evaluated patient-reported outcomes describing perceived discomfort, focusing on the resolution of symptoms like fever and chills. The ultimate measure, ACPR, represents a primary endpoint defined in studies where both the clinical symptoms are resolved and the parasite is completely cleared from the bloodstream. Findings from the studies describe patterns observed related to the measurement of specific laboratory and clinical outcomes.

Evidence in Special Patient Groups

Research was studied for use across a wide range of patients, but the body of evidence includes specific evaluations for certain vulnerable groups. This combination was evaluated in numerous studies involving pediatric populations, including infants, who represent a large population affected by malaria. Trials specifically enrolling children monitored outcomes across various age and weight groups. These studies contribute to the broader evidence landscape regarding treatment in pediatric populations.

Research also examined patients with HIV co-infection and those who are pregnant, typically in their second or third trimesters, to monitor how other drugs or physiological states may influence the measured concentrations of Artefan in the body. For these special populations, data are still emerging and results apply only to the populations studied.

Research Gaps and Areas of Uncertainty

While the evidence base is extensive, certain research limitation frames are noted in scientific literature. Data are still emerging for patients with severe underlying conditions, such as major liver or kidney impairment, meaning evidence for these specific groups is limited.

Key Studies & References

1. WHO Guidelines for the treatment of malaria (MTG) - Recommended ACTs

Common questions about Artefan (FAQ)

Q: How long does one dose of Artefan stay in my system?

Studies examining the medicine’s time in the body indicate that the long-acting component, Lumefantrine, has an elimination half-life generally ranging from three to six days. This sustained presence is described as supporting the intended sustained action against the parasite after the short treatment course is complete.

Q: How quickly does Artefan start to work after I take it?

The official product information describes the first active ingredient, Artemether, as being rapidly absorbed. Its concentration in the blood reaches a peak approximately two to three hours after administration. This rapid action is designed to quickly reduce the amount of the parasite in the blood.

Q: Is Artefan considered a short-term or long-term medication?

Artefan is a short-term medication designed for the treatment of acute infection. According to official prescribing information, the total treatment is a fixed regimen of six doses administered over a three-day (60-hour) period.

Q: What happens if I accidentally miss a dose of Artefan?

Official guidance in the product information notes that a missed dose is generally taken as soon as it is remembered. The recommendation is to then continue with the regular dosing schedule, and it is noted that the dose should not be doubled.

Q: What is the non-directive guidance for use with food?

The administration protocol describes that every dose is to be taken with food or a fatty drink, such as milk, because this significantly enhances the medicine's absorption. Taking the medicine without adequate food can potentially reduce the amount of the drug in your system, which may increase the risk of the infection returning (recrudescence).

Q: Does Artefan have a specific warning about operating heavy machinery?

Official safety information notes that dizziness, headache, and fatigue are classified as common side effects. The safety notes also indicate the uncommon possibility of somnolence (drowsiness). The product information states that these effects may impair a person's ability to drive or operate machinery.

Q: Is the medication called Artefan available in generic form?

While the specific trade name 'Artefan' may vary in availability across different countries, the active combination of Artemether/Lumefantrine is widely available. Regulatory agencies acknowledge that this combination exists in multiple generic formulations globally.

Q: Is Artefan related to any naturally occurring substances?

One of the two active ingredients, Artemether, is formally described as a synthetic derivative. This means it is chemically based on artemisinin, a compound that was originally isolated from the Artemisia annua plant.

Q: Is it okay to take Artefan if I'm taking over-the-counter pain relievers?

Information on drug interactions primarily focuses on prescription medications that affect the CYP3A4 liver enzyme or heart rhythm. Official guidance is that the use of all over-the-counter products and pain relievers should be disclosed to a prescribing healthcare provider.

Q: Why are people with kidney issues cautioned about using Artefan?

Caution is advised in individuals with severe kidney or liver impairment. Regulatory documents state that this caution is due to the lack of extensive safety data. The medicine's levels and overall safety have not been thoroughly studied in these specific patient populations.

Q: Is it normal to feel slightly nauseous when first starting Artefan?

According to official safety information, nausea is classified as a Very Common side effect. Other gastrointestinal issues like vomiting and abdominal pain are also noted as Very Common, meaning they are observed in a high percentage of patients during clinical studies.

Q: Can Artefan cause tiredness or make me sleepy?

Official safety information lists fatigue (tiredness) as a Common side effect and notes the Uncommon occurrence of somnolence (drowsiness). Dizziness is also listed as Very Common.

Q: What are the general recommendations for discontinuing Artefan treatment?

The product information emphasizes the importance of completing the full, fixed, three-day course of treatment as prescribed. Regulatory documents stress that stopping the course too early, even if symptoms begin to improve, may increase the risk of the infection returning (recrudescence).

Q: Is it common for people to switch from another drug to Artefan?

Official treatment guidelines classify this drug as a key component of the WHO-recommended strategy, especially in regions where the parasite has developed resistance to older medicines. This resistance is the primary context for its selection over certain other available treatments.

Q: Why is it important to review a full list of interactions before starting Artefan?

Reviewing the full list of interactions is emphasized because certain drug combinations pose specific risks. These risks include either increasing the chance of serious side effects (like heart rhythm abnormalities) or reducing the concentration of the medicine, which could lead to potential treatment failure.

Artefan (artemether/lumefantrine) must be stored and disposed of according to strict regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

• Temperature and Environment: The tablets must be stored at room temperature and not above 30 C. The product must be kept from freezing and stored away from heat, moisture, and direct light.
• Container and Protection: The medicine must be kept in the original container, with the container tightly closed to protect it from light.
• Child Safety: Keep the product out of the reach and sight of children.

Disposal Instructions

Any unused product or waste material must be disposed of in accordance with local requirements. The FDA advises utilizing a drug take-back program if one is available. This medicine is not currently recommended for disposal by flushing down the toilet or sink. Do not keep outdated medicine or medicine no longer needed.